Main Page


Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics. CureLab Oncology is committed to creating a family of revolutionary therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen™, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen™ reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen™. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.
Разработка SEO-Online Оптимизация сайта
Работает на Amiro.CMS - Free